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Abstract. With the development of physiologically based absorption models, there is an increased
scientific and regulatory interest in in silico modelling and simulation of drug–drug and drug–food
interactions. Clinically significant interactions between ciprofloxacin and metallic compounds are widely
documented. In the current study, a previously developed ciprofloxacin-specific in silico absorption model
was employed in order to simulate ciprofloxacin/metallic compound interaction observed in vivo.
Commercially available software GastroPlus™ (Simulations Plus Inc., USA) based on the ACAT model
was used for gastrointestinal (GI) simulations. The required input parameters, relating to ciprofloxacin
hydrochloride physicochemical and pharmacokinetic characteristics, were experimentally determined,
taken from the literature or estimated by GastroPlus™. Parameter sensitivity analysis (PSA) was used
to assess the importance of selected input parameters (solubility, permeability, stomach and small intestine
transit time) in predicting percent drug absorbed. PSA identified solubility and permeability as critical
parameters affecting the rate and extent of ciprofloxacin absorption. Using the selected input parameters,
it was possible to generate a ciprofloxacin absorption model, without/with metal cation containing
preparations co-administration, which matched well the in vivo data available. It was found that reduced
ciprofloxacin absorption in the presence of aluminium hydroxide, calcium carbonate or multivitamins/zinc
was accounted for by reduced drug solubility. The impact of solubility–permeability interplay on cipro-
floxacin absorption can be observed in the ciprofloxacin–aluminium interaction, while in ciprofloxacin–
calcium and ciprofloxacin–zinc interactions, effect of solubility was more pronounced. The results
obtained indicate that in silico model developed can be successfully used to complement relevant
in vitro studies in the simulation of physicochemical ciprofloxacin/metallic compound interactions.
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INTRODUCTION
Drug absorption is a complex process that can be affected
by numerous physicochemical, pharmaceutical and physiolog-
ical factors. With the introduction of the Biopharmaceutics
Classification System (BCS) and development of physiologi-
cally based absorption models, there is an increased scientific
and regulatory interest in in silico modelling and simulation of
drug–drug and drug–food interactions (1–6). According to the
BCS concept drug dose, solubility and intestinal permeability
are major determinants of drug absorption (1).
Gastrointestinal simulations based on the Advanced
Compartmental Absorption and Transit (ACAT) model have
become an important in silico tool to predict the in vivo drug
behaviour during drug development and quality approval
(6–9). The ACAT model contains nine compartments (stom-
ach, duodenum, jejunum 1, jejunum 2, ileum 1, ileum 2, ileum
3, caecum and ascending colon) to mimic the human gastroin-
testinal tract. Mass balance equations describe drug transport
along the gastrointestinal tract, as well as through membrane.
Default physiological parameters under fasted and fed states
are population mean values obtained from published data
including pH, volume, length, radii and transit time. Drug
diffusion coefficient, particle density, particle radius, particle
shape factor and experimentally determined solubility are
used as input parameters. The dissolution rate constant is
calculated by a modified Noyes–Whitney dissolution equation
(2). The important feature of ACAT model which contributes
to its use in biopharmaceutical drug characterization is that it
provides link between formulation performance and drug
product pharmacokinetics.
Ciprofloxacin hydrochloride is a BCS class 4 drug that
exhibits pH-dependent solubility profile and relatively narrow
absorption window in the upper small intestine (10). Reports
from in vivo studies indicate reduced ciprofloxacin bioavailabil-
ity when co-administered with a range of metallic ion containing
preparations (11–14). The absorption impairment may be sig-
nificant and potentially lead to the failure of clinical treatment
(12,13,15). Formation of nonabsorbable complex has been pos-
tulated as the interaction mechanism (11–13), although some
authors commented that other physicochemical factors, such as
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solubility, may also play a role (11). Drug solubility and perme-
ability are closely associated indicating that solubility–perme-
ability interplaymust be taken into account in order tomaximize
the overall drug absorption (16).
It has been shown in our previous study (17) that in silico
simulation can be used together with in vitro studies for the
biopharmaceutical characterization of the physicochemical
ciprofloxacin–iron interaction. This previously developed ab-
sorption model was employed in the present study in order to
simulate interactions of ciprofloxacin with aluminium, calcium
and zinc and elucidate potential interaction mechanism/s.
MATERIALS AND METHODS
In Vivo Data
Literature in vivo data related to ciprofloxacin bioavail-
ability studies, without/with metallic compounds co-adminis-
tered, were used for gastrointestinal simulation model
optimization. In the study performed by Polk et al. (13), 500-
mg ciprofloxacin tablets were administered without/with mul-
tivitamins containing zinc in a group of 12 subjects.
Multivitamins used in the Polk et al. study (13) contained
vitamin E; vitamins B1, B2, B3, B5, B6 and B12; vitamin C; folic
acid; biotin and zinc (23.9 mg) and copper (4 mg). The form of
zinc compound was not reported. The authors suggested that,
although zinc is probably responsible for the interaction, the
possibility that other components of the tablet contribute
cannot be excluded (13). The results obtained indicate that
ciprofloxacin absorption was reduced by 24% (2–50% range)
when given concomitantly with zinc containing multivitamin
product. Polk et al. (13) reported that area under the curve
(AUC) for ciprofloxacin administered with multivitamins con-
taining zinc (i.e. 11.29±2.42) is significantly different from
AUCs obtained in the two control studies (i.e. 14.46±2.33
and 15.71±2.84). Frost et al. (14) studied the effect of alumin-
ium hydroxide antacid and calcium carbonate antacid on
ciprofloxacin bioavailability. Ciprofloxacin (HCl) tablets
(750 mg) were administered: (a) alone, (b) with four 850-mg
calcium carbonate tablets and (c) with three 600-mg alumini-
um hydroxide tablets. The relative bioavailability of ciproflox-
acin when given with calcium carbonate was approximately
60% (mean AUC value 7.82±3.09) of the control value (i.e.
13.50±4.61). When ciprofloxacin (hydrochloride tablet) was
given with aluminium hydroxide, the relative bioavailability
was approximately 15% (mean AUC value 1.61±1.44).
Pharmacokinetic parameters used in gastrointestinal simula-
tion (rate constants k12, k21, volume of distribution, Vd shown
in Table I) were calculated from the in vivo data reported
following ciprofloxacin i.v. administration (18). Values for V2
and t1/2 were calculated by GastroPlus™ as a result of built-in
calculation from the PK parameters obtained from the in vivo
data (18).
Gastrointestinal Simulation
In silico absorption simulation was performed using the
commercially available software GastroPlus™ version
6.0.1004 (Simulations Plus Inc., USA) based on the ACAT
model. In in vivo studies (13,14), ciprofloxacin was taken
concomitantly with metallic cations containing preparations
after an overnight fast, so Human Physiology Fasted mode
was used for simulation. Model optimization was performed
based on the set of input parameters describing drug and
dosage form characteristics, which were determined experi-
mentally, taken from the literature or estimated by the soft-
ware (17). A summary of the input parameters used is given in
Table I. GastroPlus™ default value for drug particle density
was used. For the diffusion coefficient, GastroPlus™ estimat-
ed value was used based on ciprofloxacin molecular weight.
The blood–plasma concentration ratio was set to 1 as default
GastroPlus™ value. Experimentally determined solubility of
ciprofloxacin hydrochloride in water (corresponding to the
final pH value 4.04) was used as a reference. Peff value was
estimated from data on drug bioavailability assuming that
there is no substantial loss by first pass elimination (19) and
that fraction dose absorbed (Fa) could be considered equal to
drug absolute bioavailability.
The exponential relationship for fraction absorbed vs.
effective permeability established by Amidon et al. (1) was
employed:
Fa ¼ 1 − e−1:47Peff
   100
The absorption scale factors (ASF) in Physiology tab are used
to demonstrate the changes in permeability as the drugs trav-
els along the GI tract. ASF scale the effective permeability to
account for variations in absorption rate-determining effects
(e.g. pH value, the presence of influx and efflux transporters)
that differ from one compartment to another (2). The ASF
are, generally, calculated automatically based on drug physi-
cochemical characteristics, but can be further adjusted based
Table I. Summary of Ciprofloxacin Input Parameters in GastroPlus
Parameters Value
Molecular weight 385.8 g/mol
logP 1.32a
pKa1 8.62
b
pKa2 6.16
b
Dose 500 mg
Solubility at pH 4.04 42 mg/mlc
Diffusion coefficient 0.75×105 cm2/sd
Drug particle density 1.2 g/mle
Peff (human jejunal permeability) 1.57×10
−4 cm/sf
Body weight 70 kg
Blood/plasma concentration ratio 1e
Unbound percent in plasma 70%g
Clearance 35 or 37 l/hh
Volume of distribution, Vc 0.56 l/kg
i
Peripheral volume, V2 1.347 l/kg
j
Elimination half-life, T1/2 (h) 4.08
j
Distribution rate constants
k12 2.3753 l/h
i
k21 0.98752 l/h
i
a From (20)
b From (21)
cExperimental value
dGastroPlus estimated value based on molecular weight
eGastroPlus default values
f See text
g From (22)
hGastroPlus optimized
iCalculated by Kinetica program from (18)
jGastroPlus calculated (built-in calculation from PK parameters)
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on the drug disposition observed in the human in vivo studies.
ASF values relevant to ciprofloxacin hydrochloride were fur-
ther optimized to reflect the in vivo data indicating rapid drug
absorption in the proximal segments of the gastrointestinal
tract and narrow absorption window in the upper small intes-
tine (10) as reported previously (17). Consequently, they were
scaled to zero below the ‘jejunum 2’ compartment. The pH
value in ‘duodenum’ compartment was adjusted to 4.04 in
accordance with experimental data obtained (pH value of
saturated ciprofloxacin hydrochloride solution). The proposed
adjustment was justified based on relatively high ciprofloxacin
concentration following gastric emptying of a dissolved drug,
relatively low fluid volume available (23) and low buffer ca-
pacity (24) in the proximal part of intestine. The relevant
percent prediction error (PE %) values between the in vivo
observed and in silico predicted pharmacokinetic parameters
were calculated as follows (25):
PE %ð Þ ¼ PKpredicted−PKobserved
PKobserved
 100
Parameter Sensitivity Analysis
Parameter sensitivity analysis (PSA) was used to assess
the importance of selected input parameters (solubility, per-
meability, stomach residence time and intestinal transit time)
in predicting the fraction of drug absorbed. During PSA, only
one parameter is varied at a time while all other parameters
are held at their baseline values. Solubility was varied in the
range 0.1–100 mg/ml, while effective drug permeability was
varied in the range from 0.79 to 3.14×10−4 cm/s, covering one
half to 2-fold input value (i.e. according to the default
GastroPlus™ settings). Stomach and small intestine transit
times were evaluated separately in order to assess the effects
of residence time in stomach and small intestine on the
percent of drug absorbed. As residence time in the stomach
is known to be highly variable, it was varied in the range 0.25–
3 h, while the transit time in small intestine has been reported
to be relatively constant and physiologically relevant range of
3 to 4 h was employed (26,27).
RESULTS
In Silico Simulation of Ciprofloxacin Absorption
Gastrointestinal simulation for ciprofloxacin (HCl) tab-
lets, based on the input physicochemical and pharmacokinetic
data presented in Table I, was performed using the GastroPlus
Single Simulation. The predicted ciprofloxacin plasma profiles
are presented in Fig. 1a, together with the mean plasma pro-
files observed in vivo after administration of tablets containing
500 mg (13) or 750 mg (14) of ciprofloxacin hydrochloride.
The best fit of the actual data observed in vivo when cipro-
floxacin tablets were given without metallic compounds (‘con-
trol’ study) was obtained with the input solubility of 42 mg/ml,
corresponding to the experimentally obtained aqueous solu-
bility of ciprofloxacin hydrochloride. The simulation results
indicated fraction of drug absorbed of 80.8% and 81% for the
‘control’ studies (Fig. 1b).
The predictability of the generated absorption model was
measured by the percent prediction error (PE%) between the
predicted and in vivo observed data. The predicted
pharmacokinetic parameters and those observed in vivo are
presented in Table II. The percent prediction errors obtained
were less than 10% for both Cmax and AUC0− t, indicating
good predictability. In addition, regression coefficients for
in silico predicted ‘control’ profiles were 0.99 and 0.93,
indicating that in silico predicted profiles matched well the
in vivo data reported by Polk et al. (13) and Frost et al.
(14), respectively.
PSA Analysis
The results obtained from PSA analysis are shown in
Fig. 2a–d. The outputs indicated that, within the range of
values tested, the percent of ciprofloxacin absorbed was sen-
sitive to solubility and permeability, while it was less sensitive
to variation in stomach residence time and small intestine
transit time. The results obtained show that the percent of
ciprofloxacin absorbed is not sensitive to change in stomach
residence time in the range of 0.25–3 h. However, the percent
of ciprofloxacin absorbed increased slightly with the increase
in small intestine transit time. Based on the PSA performed
for ciprofloxacin solubility in the range from 0.1 to 100 mg/ml,
almost complete absorption (Fa=80%) was achieved with
solubility value 42 mg/ml, reflecting ciprofloxacin hydrochlo-
ride aqueous solubility. Based on the PSA performed for
ciprofloxacin permeability in the range from 0.79 to 3.14×
10−4 cm/s, it was demonstrated that almost complete
absorption is expected if effective permeability is equal
to or higher than 1.57 × 10−4 cm/s, indicating that
ciprofloxacin absorption is not permeability limited, but
could be compromised if less permeable interaction
adduct is formed.
Ciprofloxacin/Metallic Ion Interaction
In order to investigate the influence of aluminium, calci-
um and zinc compounds on ciprofloxacin bioavailability, the
simulated Cp−time data were compared with the mean plas-
ma profiles observed in vivo after administration of ciproflox-
acin tablets with aluminium hydroxide (14), calcium carbonate
(14) and multivitamins with zinc (13). Taking into account the
expected influence of (a) solubility and (b) permeability as
identified above in the PSA analysis and the possible interplay
between solubility and permeability, three cases were consid-
ered for each ciprofloxacin/metallic cation interaction:
Case 1 In this case, Peff value remained unchanged (Peff=
1.57×10−4 cm/s), while solubility input value was
optimized. It was found that reduced ciprofloxacin
absorption observed in the presence of aluminium
hydroxide was best described when ciprofloxacin
solubility was reduced to 0.07 mg/ml (regression
coefficient r2=0.8). The related in silico simulated
and in vivo observed Cp−time profiles are presented
in Fig. 3a. In the case of calcium carbonate, reduced
ciprofloxacin absorption was best described when
ciprofloxacin solubility was optimized to 1 mg/ml
(r2=0.97). Relevant in silico simulated and in vivo
observedCp−time profiles are presented in Fig. 4a.
Ciprofloxacin absorption when administered with
multivitamin containing zinc preparation was best
described when ciprofloxacin solubility was
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optimized to 29 mg/ml (r2=0.93). Relevant in silico
simulated and in vivo observed Cp−time profiles
are presented in Fig. 5a.
Case 2 In the second case, permeability input values have
been optimized, while the solubility remained un-
changed (i.e. experimentally obtained ciprofloxa-
cin aqueous solubility 42 mg/ml). The results
obtained show that reduced ciprofloxacin absorp-
tion observed in the presence of aluminium hy-
droxide or calcium carbonate was best described
when permeability was optimized to 0.1×10−4 cm/s
(r2=0.74), or 0.8×10−4 cm/s (r2=0.86), respectively.
The corresponding in silico simulated plasma
concentration profiles are presented in Figs. 3a
and 4a. Ciprofloxacin absorption in the presence
of multivitamin containing zinc preparation was
well described in silico when permeability input
value was optimized to 1.2×10−4 cm/s (r2=0.84).
Relevant in silico simulated profile is presented in
Fig. 5a.
Case 3 In the third case, solubility and permeability input
values have been optimized simultaneously. The
results obtained indicate that reduced ciprofloxacin
absorption in the presence of aluminium hydroxide
was best described when solubility and permeability
were optimized to 0.3 mg/ml and 0.8×10−4 cm/s,
respectively (r2=0.80). The corresponding in silico
simulated plasma concentration profile is presented
in Fig. 3a. In the case of calcium carbonate, reduced
ciprofloxacin absorption was best described when
ciprofloxacin solubility and permeability were
optimized to 2 mg/ml and 1.2 × 10−4 cm/s,
respectively (r2=0.96). Relevant in silico simulated
profile is presented in Fig. 4a. Ciprofloxacin
absorption in the presence of multivitamin
containing zinc preparation was well described in
Fig. 1. In silico simulated and in vivo observed ciprofloxacin plasma Cp−time profiles following oral administration of 500 or 750 mg
ciprofloxacin tablet (13,14) (a) and predicted absorption profiles (b)
Table II. In Silico Predicted and In Vivo Observed Pharmacokinetic Parameters
Study
Cmax (μg/ml) AUC0−t (μgh/ml)
ReferenceObserved Predicted PE % Observed Predicted PE %
Control 1 2.33 2.44 4.70 13.67 13.35 2.30 (13)
Control 2 1.95 2.14 9.74 10.92 11.55 5.70 (14)
Case 1 (optimized solubility)
Ciprofloxacin/aluminium interaction 0.21 0.21 0 1.20 1.17 2.50 (14)
Ciprofloxacin/calcium interaction 1.08 1.05 2.80 5.88 5.31 9.70 (14)
Ciprofloxacin/multivitamins with zinc interaction 1.67 1.76 5.39 10.20 9.72 4.70 (13)
Case 2 (optimized permeability)
Ciprofloxacin/aluminium interaction 0.21 0.21 0 1.20 1.63 35.8 (14)
Ciprofloxacin/calcium interaction 1.08 1.18 9.3 5.88 6.5 10.54 (14)
Ciprofloxacin/multivitamins with zinc interaction 1.67 1.59 4.8 10.20 11.53 13.04 (13)
Case 3 (optimized solubility and permeability)
Ciprofloxacin/aluminium interaction 0.21 0.21 0 1.20 1.19 0.80 (14)
Ciprofloxacin/calcium interaction 1.08 1.05 2.80 5.88 5.47 6.97 (14)
Ciprofloxacin/multivitamins with zinc interaction 1.67 1.75 4.79 10.20 9.53 6.57 (13)
AUC area under the curve, PE % percent prediction error values between the in vivo observed and in silico predicted pharmacokinetic
parameters
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silico when solubility and permeability input values
were optimized to 27 mg/ml and 1.3×10−4 cm/s (r2=
0.95). Relevant in silico simulated profile is
presented in Fig. 5a.
The predicted pharmacokinetic parameter values (Cmax
and AUC) are given in Table II, together with the data ob-
served in the in vivo studies. The calculated percent prediction
error values for the in silico drug plasma concentration pro-
files generated based on the optimized solubility values were
less than 10% for both Cmax and AUC (Table II). The calcu-
lated percent prediction error values for the in silico drug
plasma concentration profiles generated based on the opti-
mized permeability values were less than 10% for Cmax
(Table II), while, for AUC, the PE % were 35.8, 10.54 and
13.04 (for aluminium, calcium and multivitamin containing
zinc co-administration, respectively). The calculated percent
prediction error values for the in silico drug plasma concen-
tration profiles generated based on the optimized solubility
and permeability values were less than 10% for both Cmax and
AUC (Table II).
According to the percent prediction error values pre-
sented in Table II, it would be expected that ciprofloxacin
absorption in the presence of metallic cations is more affected
Fig. 2. Parameter sensitivity analysis. The dependence of fraction ciprofloxacin absorbed on different input parameters: a solubility, b
permeability, c stomach transit time and d small intestine transit time
Fig. 3. GastroPlus™ predicted (solubility, permeability or solubility–permeability optimized) and in vivo observed mean ciprofloxacin plasma
Cp−time profiles with aluminium hydroxide tablets co-administered (a) and predicted absorption profile (b)
274 Stojkovic et al.
by solubility than by permeability variation. The impact of
solubility–permeability interplay on ciprofloxacin absorption
can be observed in the case of ciprofloxacin–aluminium inter-
action where optimized values for both solubility and perme-
ability were notably lower compared to control input values.
In the case of ciprofloxacin–calcium and ciprofloxacin–zinc
interactions, effect of solubility was more pronounced and
optimized solubility values obtained in case 3 were similar to
values obtained in case 1. The simulated ciprofloxacin absorp-
tion profiles in the presence of aluminium, calcium and zinc
are presented in Figs. 3b, 4b and 5b, respectively.
GastroPlus™ generated regional absorption profile of
ciprofloxacin showed that around 81% of the dose adminis-
tered was absorbed in the proximal parts of GIT. In the
presence of metallic compounds, ciprofloxacin absorption
was reduced mainly in duodenum and jejunum 1 and 2
(Fig. 6).
DISCUSSION
Gastrointestinal simulation was successfully employed to
develop an absorption model for ciprofloxacin immediate
release dosage forms. Using the input physicochemical and
pharmacokinetic parameters presented in Table I, it was pos-
sible to generate the ciprofloxacin absorption profile without
metallic cation co-administration that matched well in vivo
observed data. The predicted fractions of ciprofloxacin
absorbed (Fa) for the two ‘control’ studies were 80.8% and
81%, respectively (Fig. 6). The results obtained are in accor-
dance with the published data stating 60–80% bioavailability
of ciprofloxacin after oral administration (28–30).
Literature data related to the effect of metallic cations
(aluminium, calcium, zinc) on the solubility of fluoroquino-
lones are somewhat contradictory. While there are reports
indicating increased solubility (31) or no effect (32) in the
presence of divalent or trivalent cations, Turel (33) attributed
the fluoroquinolone–metallic cation interaction to the de-
creased fluoroquinolone solubility.
Average absolute percent prediction error (PE %) of
10% or less for Cmax and AUC indicates good predictability
of the in silico model developed (25). PE % values for the
Cmax and AUC obtained were lower in the case of gastroin-
testinal simulation model based on the optimized solubility
(Table II). This model gave good prediction of ciprofloxacin
Fig. 4. GastroPlus™ predicted (solubility, permeability or solubility–permeability optimized) and in vivo observed mean ciprofloxacin plasma
Cp−time profiles with calcium carbonate tablets co-administered (a) and predicted absorption profile (b)
Fig. 5. GastroPlus™ predicted (solubility, permeability or solubility-permeability optimized) and in vivo observed mean ciprofloxacin plasma
Cp−time profiles with multivitamin preparation containing zinc co-administered (a) and predicted absorption profile (b)
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oral absorption with metallic cation containing products (alu-
minium, calcium, zinc) co-administration. Values of the regres-
sion coefficients further confirm good agreement between the
in silico simulated and in vivo observed data.
The absorption model based on optimized permeability
value was able to predict well the Cmax (PE less than 10% in
all the simulations), while high degree of deviation from the
mean in vivo estimated values were observed for AUC
(Table II). When interpreting the significance of AUC value
prediction, it should be considered that PE % was calculated
based on the mean AUC values reported from a particular
in vivo data set (13,14). Taking into account that reported
AUC values after oral administration of ciprofloxacin tablets
with multivitamins containing zinc varied between 8.48 and
15.03 μgh/ml (13), the simulated value of 11.53 μgh/ml can be
considered as a reasonable estimate. In addition, Frost et al.
(14) reported that the average area under the ciprofloxacin
serum concentration time curve was reduced after concomi-
tant calcium carbonate or aluminium hydroxide product ad-
ministration, but the effect in individual subjects varied in the
case of calcium, while the effect of aluminium hydroxide was
similar in all volunteers. According to the values of the re-
gression coefficients obtained in case 2 (varying permeability
value), poor correlation was found between in vivo observed
and in silico simulated profiles. The absorption model based
on simultaneously optimized solubility and permeability val-
ues was able to predict well the Cmax and AUC values (PE less
than 10% in all the simulations) (Table II) indicating the
possible impact of solubility–permeability interplay in the
drug absorption process.
The regional absorption profiles (Fig. 6) indicate predom-
inant ciprofloxacin absorption in the proximal part of the
gastrointestinal tract and are consistent with data reported
from the in vivo remote control capsule study (10). In addi-
tion, the adjusted ASF values in the present model were in
accordance with the data on regional drug absorption
obtained by remote-controlled drug delivery device (10).
Ciprofloxacin is generally absorbed by passive diffusion (34),
and it may be assumed that observed absorption behaviour is
probably due to high contribution of paracellular permeability
in the upper parts of intestine. Such data suggest the existence
of a narrow absorption window in the proximal intestine and
indicate that potential interactions occurring after drug inges-
tion may markedly affect its bioavailability. In addition, in-
complete drug absorption was observed in in silico simulated
ciprofloxacin absorption profiles with metallic cations (alu-
minium, calcium, zinc) co-administered.
PSA indicate that the percent of ciprofloxacin absorbed
was not influenced by prolonged residence time in stomach,
while it was slightly increased with prolonged transit time in
small intestine. It has been reported that ciprofloxacin dem-
onstrates rapid absorption in the proximal part of the intestine
(35). Rapid absorption is consistent with the relatively short
tmax values (in the range of 0.58–1.75 h) and relatively high
absorption rate constants, with the values reported being in
the range of 1.5–3.6 h−1 (28–30). Relatively narrow range in
which the intestinal transit time was varied may be also
responsible for the negligible effect observed in PSA.
According to the in silico results obtained, ciprofloxacin
absorption in the presence of aluminium hydroxide is more
sensitive to solubility than to permeability variation and
certain solubility–permeability interplay was evident.
Literature data indicate formation of more soluble
ciprofloxacin complexes with aluminium (31,36) compared to
ciprofloxacin in the range of pH 1–8. It was reported, based on
in vitro permeability studies, that ciprofloxacin–aluminium
complex does not permeate intestinal mucosal membrane
(37). Ciprofloxacin tablet dissolution in vitro in the presence
of aluminium hydroxide has been shown to be retarded
(38,39), and also, some authors suggest that adsorption of
fluoroquinolones on the aluminium hydroxide particles could
significantly decrease the amount of drug available for
absorption (39,40). Currently, it is not possible to include all
these phenomena in the in silico simulation, which emphasize
the need for complementary in vitro and in vivo studies in
order to assess the mechanisms involved. In addition, the role
Fig. 6. Regional absorption of ciprofloxacin with/without metallic cations (zinc, calcium,
aluminium) co-administration (estimated by GastroPlus™ simulation)
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of solubility–permeability interplay in drug absorption should
not be neglected.
Žakelj et al. (37) reported that ciprofloxacin permeability
was not significantly influenced by the presence of Ca2+.
According to their results and the results obtained from in
silico simulations, reduced ciprofloxacin bioavailability, which
occurs when it is taken concomitantly with preparations
containing calcium, is not necessarily a consequence of
diminished intestinal drug permeability. In silico optimized
ciprofloxacin solubility in the presence of calcium carbonate
was found to be 1 mg/ml. We have shown earlier that addition
of calcium carbonate elevates pH value of the dissolution
media above 6 and affects ciprofloxacin solubility resulting in
appearance of notable precipitation (41). Cumulative amount
of drug dissolved was reduced by more than 70% (41). In
silico optimized ciprofloxacin solubility (1 mg/ml) was similar
to concentration of ciprofloxacin dissolved in reactive media
containing calcium carbonate which was found to be 0.83 mg/
ml (41). The simulation results show incomplete drug
absorption (Fig. 4b) in the presence of calcium carbonate,
indicating that absorption is likely to be solubility-limited at
pH values above 6 (i.e. dose number ∼2).
In the case of ciprofloxacin–zinc interaction, when zinc
compound was administered as the mixture with other miner-
als and vitamins, it was not possible to distinguish the influ-
ence of zinc on ciprofloxacin absorption. The simulation
results suggest that drug absorption when co-administered
with multivitamins containing zinc was not impaired in ‘duo-
denum’, whereas it was substantially decreased in ‘jejunum 1
and 2’ (Fig. 6). Formation of low soluble ciprofloxacin–zinc
complexes was described in the literature (42). In silico simu-
lation of ciprofloxacin–zinc interaction identified decreased
solubility as the critical factor affecting the rate and the extent
of drug absorption, which is consistent with literature data
suggesting formation of low soluble ciprofloxacin–zinc
complexes.
CONCLUSION
The data presented indicate the potential of ‘gastrointes-
tinal simulation technology’ to be used for prediction of cipro-
floxacin metallic ion interaction. It was possible to use
common model for simulation of ciprofloxacin absorption
without/with metallic cations co-administration. It should be
stressed that, in order to obtain meaningful in silicomodelling,
the necessary input data have to be carefully evaluated if
taken from the literature or experimentally verified by
performing relevant in vi tro and in vivo studies .
Ciprofloxacin absorption in the presence of metallic com-
pounds is mainly impaired in the proximal parts of the intes-
tine, leading to a significant decrease in ciprofloxacin
bioavailability and potential failure of therapeutic effect. It
was found that reduced solubility of the interaction adduct
may be assumed responsible for reduced ciprofloxacin bio-
availability in the presence of metallic ions containing prepa-
rations. Based on the results of the regional drug absorption
study, it can be expected that ciprofloxacin–metallic cation
interaction may be circumvented by administering metallic
ions containing products 2 h after the ciprofloxacin dose, when
majority of drug has been absorbed.
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